Prescribing guide
Enspryng (satralizumab-mwge)Pre-dose screening, loading doses, liver and neutrophil monitoring and prior authorization criteria for NMOSDFor prescribers and their offices treating neuromyelitis optica spectrum disorder (NMOSD): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. HBV, TB and liver transaminase plus bilirubin screening before dose 1, live vaccines at least 4 weeks before, ENSPRYNG Start Form, prior authorization, and HCP-guided first injection.
Example PA threshold
FEP example: age 18 or older, anti-AQP4 antibody positive, baseline AST, ALT and bilirubin, agreement to monitor AST, ALT and neutrophils, no active HBV, no active or untreated latent TB.
Monitoring
ALT and AST every 4 weeks for 3 months, then every 3 months for one year. Neutrophils at 4 to 8 weeks, then at clinical intervals; infection check before every dose.
Support line
ENSPRYNG Access Solutions, 1-844-677-7964 (1-844-NSPRYNG), Mon to Fri 6am to 5pm PT; as little as $0 per 30-day supply on eligible commercial plans, up to $20,000 a year.
Give your patient their plan
A one-page handout for starting Enspryng, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/enspryngBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in ENSPRYNG Access Solutions | Patient and prescriber both complete the ENSPRYNG Start Form (e-submit or download). A Patient Navigator is assigned and works with the office and specialty pharmacy on coverage and getting the medicine. | Patient Navigators |
| Benefits investigation and PA | ENSPRYNG Access Solutions handles access and reimbursement support after prescribing, including benefits investigations and prior authorizations. Offices can enroll patients and manage service requests through My Patient Solutions. | Genentech HCP FAQ |
| Complete pre-dose screening | HBsAg and anti-HBV tests; TB risk evaluation and latent TB testing; liver transaminases and serum bilirubin. Consult liver disease experts for HBcAb+ or HBsAg+ patients, and infectious disease experts for active or inadequately treated TB. | FDA label |
| Vaccines | Live or live-attenuated vaccines at least 4 weeks before initiation; non-live vaccines, whenever possible, at least 2 weeks before. Live vaccines are not recommended during treatment. | FDA label |
| First injection and training | Perform the first injection under the guidance of a qualified HCP. Train the patient or caregiver and assess their ability to inject before home use. | FDA label |
| Supplemental training | Genentech Clinical Education Managers offer no-cost one-on-one sessions, in person or virtual, including supplemental injection training after the doctor has trained and approved self-injection. Intended mainly for the first year; CEMs do not give medical advice. | Clinical Education Managers |
| Product and fill cadence | One carton holds one single-dose 120mg/mL prefilled syringe (NDC 50242-007-01) or one 120mg/mL autoinjector (NDC 50242-007-55). Each dose is one carton, so maintenance is one carton every 4 weeks after 3 loading cartons. The 180mg/1.5mL autoinjector (NDC 50242-005-01) is for TED patients above 100kg, not NMOSD. | FDA label |
| Sample doses | Genentech's sample program provides the first 2 months of treatment, 3 loading doses and the first maintenance dose, to practices. Request through the local Genentech representative or the Sample Accountability Call Center, 1-866-736-2717, Monday to Friday 8 AM to 6 PM ET. Annual per-HCP limits apply. | Genentech sample program |
| Storage counseling | Refrigerate at 2°C to 8°C (36°F to 46°F) in the original carton; do not freeze or shake. Up to 8 days total out of refrigeration at no more than 30°C (86°F). Warm 30 minutes outside the carton before use. | FDA label |
| Co-pay program | ENSPRYNG Co-pay Program: commercial insurance, age 18 or older or a caregiver, US or US Territories, as little as $0 per 30-day supply, up to $20,000 per calendar year. Excludes Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD and TRICARE. | Genentech financial help |
| Denial or no coverage | After a denial (following any required PA), the patient can apply to the Genentech Patient Foundation without proof of appeal. Patient Consent Form plus Prescriber Foundation Form; processed within 5 business days of both. Foundation Specialist 888-941-3331. | Genentech Patient Foundation |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, April 1, 2026. Approval twelve months at first, up to 15 syringes. Renewals are 12 months at a time, up to 3 syringes every 84 days, when the patient has had fewer relapses on Enspryng. This policy was approved on March 6, 2026 and cites a March 2022 label. It predates the June 2026 and October 2026 labels. The current label lists autoinjectors and adds a thyroid eye disease use. The NMOSD dose, tests and monitoring it describes match the current label. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Neuromyelitis optica spectrum disorder, age 18 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Anti-aquaporin-4 (AQP4) antibody positive | Antibody result with date | FEP Blue policy |
| Baseline liver tests | AST, ALT and serum bilirubin assessed before initiating | Lab results with date | FEP Blue policy |
| Monitoring plan | Prescriber agrees to monitor AST, ALT and neutrophil counts | Monitoring plan in the note | FEP Blue policy |
| Hepatitis B and tuberculosis | No active hepatitis B infection; no active or untreated latent tuberculosis | HBV screening, TB test result and any treatment history | FEP Blue policy |
| Vaccines | Not given concurrently with live vaccines | Vaccine history and plan | FEP Blue policy |
| Renewal | Fewer relapses on Enspryng; first approval 15 syringes for 12 months, renewals 3 syringes per 84 days for 12 months | Relapse history since start | FEP Blue policy |
Enspryng dosing and titration
| When | Label | Source |
|---|---|---|
| Week 0 (day 1) | 120mg SC, first loading dose, under the guidance of a qualified HCP. | FDA label |
| Week 2 (day 15) | 120mg SC, second loading dose. | FDA label |
| Week 4 (day 29) | 120mg SC, third loading dose. | FDA label |
| Every 4 weeks | 120mg SC maintenance, starting week 8. Steady state is reached after the 8-week loading period. | FDA label |
| Injection technique | Abdomen or thigh; avoid 2 inches (5cm) around the navel; rotate sites at least 1 inch (2.5cm) from the last. Inject the full 1mL from the syringe; use within 5 minutes of removing the cap. | FDA label |
| Missed dose | Under 8 weeks in maintenance or a missed loading dose: give as soon as possible and reset. If loading dose 2 is late, give dose 3 two weeks later; if dose 3 is late, the first maintenance dose comes 4 weeks later. From 8 to under 12 weeks: weeks 0 and 2, then every 4 weeks. At 12 weeks or more: weeks 0, 2 and 4. | FDA label |
| Interruptions | Delay for active infection, including localized infection, until resolved. Interrupt for neutrophils below 1.0 x 10^9/L confirmed on repeat until above 1.0 x 10^9/L. | FDA label |
| Pediatric and geriatric | Safety and effectiveness not established in pediatric patients. Too few patients 65 and older in trials; population PK showed no age effect. | FDA label |
| Other indication | Thyroid eye disease in adults (October 2026) uses weight-based dosing, 120mg for 40 to 100kg and 180mg above 100kg; not covered on this page. | FDA letter |
Monitoring the Enspryng label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before dose 1 | HBV, TB, liver transaminases and serum bilirubin | Contraindicated with active HBV or active or untreated latent TB; caution if AST or ALT above 1.5x ULN | FDA label |
| Every 4 weeks for 3 months, then every 3 months for 1 year | ALT and AST | Above 5x ULN: discontinue. With any bilirubin rise, do not reinitiate. Without it, restart after normalization per Table 3; under 12 weeks since the last dose, every 4 weeks; 12 weeks or more, reload at 0, 2 and 4 weeks. Monitor closely; stop for good with any later rise | FDA label |
| 4 to 8 weeks after initiation, then at clinical intervals | Neutrophil count | Below 1.0 x 10^9/L confirmed on repeat: interrupt until above 1.0 x 10^9/L. Below 1 x 10^9/L in 10% vs 9% placebo (Study 1) and 15% vs 4% (Study 2) | FDA label |
| Before each dose | Active infection, including localized | Delay until resolved. Study 1 infections 51 vs 108 per 100 patient-years; Study 2 168 vs 143. Monitor for TB even if initial testing was negative | FDA label |
| Ongoing | Hypersensitivity | Rash, urticaria and fatal anaphylaxis reported with other IL-6 receptor antagonists. No further doses after serious allergic symptoms until evaluated by an HCP | FDA label |
| Laboratory shifts (NMOSD trials) | Platelets, lipids, fibrinogen, complement | Platelets below LLN 26% vs 5% (Study 1), none below 50 x 10^9/L. Cholesterol above 300mg/dL 12% and 15% vs 0%. Median fibrinogen reduction 38% and 33% | FDA label |
Enspryng drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| CYP450 substrates | No formal drug interaction studies. Suppressing IL-6 signaling from the low baseline levels in NMOSD is expected to have a minor impact on exposure of CYP450-metabolized drugs; clinical significance unknown | FDA label |
| Concurrent immunosuppressants | Study 2 used azathioprine, mycophenolate mofetil or oral corticosteroids alongside Enspryng. Most common infections above placebo there were nasopharyngitis 31%, URTI 19% and pharyngitis 12% | FDA label |
| Vaccines | Live or live-attenuated vaccines not given concurrently; live at least 4 weeks and non-live, when possible, at least 2 weeks before initiation | FDA label |
| Infants exposed in utero | Weigh risks and benefits before live or live-attenuated vaccines; monoclonal antibody transfer is greatest in the third trimester | FDA label |
| Pregnancy and lactation | No adequate human data; use in pregnancy only if benefit justifies risk. NMOSD pregnancy registry 1-833-277-9338. Excreted in monkey milk; no human milk data | FDA label |
| Contraindicated | Known hypersensitivity to satralizumab or inactive ingredients, active hepatitis B, active or untreated latent tuberculosis | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older and a positive AQP4 antibody test. It also asks for liver tests before starting and a plan to monitor liver enzymes and neutrophils. The neurologist's records usually answer what the plan is asking for.
- Screening results are missingHepatitis B, tuberculosis and liver test results are needed before the first dose. The policy also asks that there be no active hepatitis B and no active or untreated latent tuberculosis.
- Waiting on the insurance approvalGenentech's site for doctors describes free sample doses for practices that cover the first 2 months, the 3 starting doses and the first every-4-weeks dose. Ask your neurologist whether the office can use them.
- The plan says no after reviewGenentech says a patient whose plan denied coverage, after any required prior authorization, can apply to the Genentech Patient Foundation. Proof of an appeal is not needed to apply.
- A copay you cannot payCommercial insurance: the ENSPRYNG Co-pay Program, as little as $0 per 30-day supply, up to $20,000 a calendar year. Medicare, Medicare Advantage, Medicaid, VA, DoD and TRICARE are excluded. Our help paying page lists charity funds that may cover what remains.
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Genentech points to independent foundations, which set their own rules. The Genentech Patient Foundation gives free Enspryng to eligible people, including uninsured people with incomes under $150,000.
- The next carton has not shippedEach carton holds one dose, so each dose needs its own fill. Your Patient Navigator works with the doctor's office and specialty pharmacy, and takes calls at 1-844-677-7964 throughout your treatment.
- The renewal after a yearThe FEP policy renews for 12 months at a time when your neurologist documents fewer relapses on Enspryng. Renewals allow 3 syringes every 84 days. Ask the office when the renewal is due.
ENSPRYNG Access Solutions
- A Patient Navigator who explains your coverage, helps with the co-pay program and works with the doctor's office or specialty pharmacy to get your medicine
- The ENSPRYNG Co-pay Program, as little as $0 per 30-day supply for eligible commercial insurance, up to $20,000 a calendar year
- Co-pay help is not open to Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE or other government coverage, under the program's terms
- The Genentech Patient Foundation, free Enspryng for eligible people who are uninsured, whose plan does not cover it, or whose costs are high for their income. Foundation Specialists answer at 888-941-3331
- Referrals to independent co-pay foundations, which set their own rules and which people with Medicare or Medicaid can also contact
- Clinical Education Managers, Genentech employees who offer free extra injection training in the first year, after your doctor has trained and approved you
Questions prescribers' offices ask about Enspryng
What is the Enspryng loading dose for NMOSD?
The October 2026 label gives 120mg SC at weeks 0, 2 and 4, then 120mg every 4 weeks. The NMOSD dose is fixed, not weight-based. The first injection is given under the guidance of a qualified healthcare professional; the patient or caregiver may self-inject after training if the HCP judges it appropriate.
What labs are required before starting Enspryng?
Three assessments, per the October 2026 label: HBV screening, TB evaluation with latent infection testing, and liver transaminases plus serum bilirubin. Active HBV and active or untreated latent TB are contraindications. Use caution if AST or ALT is above 1.5x ULN. Give live vaccines at least 4 weeks and, whenever possible, non-live vaccines at least 2 weeks before initiation.
How often should LFTs be checked on Enspryng?
Every 4 weeks for the first 3 months, per the October 2026 label, then every 3 months for one year, then as clinically indicated. Above 5x ULN, discontinue. With any bilirubin elevation, reinitiation is not recommended; without it, restart per label Table 3 once levels normalize, after a benefit-risk assessment.
What if an Enspryng dose is missed?
Under 8 weeks since the last dose, or a missed loading dose, give it as soon as possible, per the October 2026 label (Table 2). From 8 to under 12 weeks, give doses at 0 and 2 weeks, then every 4 weeks. At 12 weeks or more, repeat the full 0, 2 and 4 week loading schedule.
What do insurers ask for to approve Enspryng for NMOSD?
The FEP policy shown here took effect April 1, 2026 and cites a March 2022 label. It asks for age 18 or older, AQP4 antibody positivity, baseline AST, ALT and bilirubin, and agreement to monitor AST, ALT and neutrophils. It excludes active HBV, active or untreated latent TB and concurrent live vaccines. It approves 15 syringes for 12 months, then 3 per 84 days with fewer relapses.
Free email alert
Get an email when the Enspryng label changes
One email the day the FDA revises the Enspryng prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Enspryng only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - ENSPRYNG- satralizumab injection, solution (prescribing information revised October 2026, SPL version 16, Medication Guide and Instructions for Use), Genentech, via DailyMed, 2026-10-23.
- openFDA drug label record for ENSPRYNG, set ID 64c156a4-9bad-4d45-a294-0733c141f47b, SPL version 15, effective June 22, 2026, FDA, openFDA, 2026-06-22.
- Financial Assistance Options | ENSPRYNG (satralizumab), Genentech, 2026-11-08.
- Patient Navigators | ENSPRYNG (satralizumab), Genentech, 2026-11-08.
- Apply for Financial Support | ENSPRYNG (satralizumab), Genentech, 2026-11-08.
- Clinical Education Managers | ENSPRYNG® (satralizumab), Genentech, 2026-11-08.
- Treatment Schedule | ENSPRYNG® (satralizumab), Genentech, 2026-11-08.
- Financial Support FAQs | ENSPRYNG (satralizumab), Genentech, 2026-11-08.
- Genentech: Apply for Help, Genentech, 2026-11-08.
- Quick Start with ENSPRYNG® (satralizumab), Genentech, 2026-11-08.
- Eligibility and Enrollment | ENSPRYNG (satralizumab), Genentech, 2026-11-08.
- Pharmacy Policy 5.99.019, Enspryng, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- BLA 761149/S-008 supplement approval letter, thyroid eye disease, FDA, 2026-10-15.
- BLA 761149/S-5 supplement approval letter, pregnancy safety study contact information, FDA, 2022-09-14.
- BLA 761149/S-2 supplement approval letter, body weight data corrections, FDA, 2021-05-03.
- BLA 761149 approval letter, Enspryng (satralizumab-mwge) injection for NMOSD, FDA, 2020-08-14.
A reference drawn from the October 23, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 8, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.